Successful phase III in UC, strengthening the case for strategic M&A
Abivax reported strong topline results from its phase III induction trials evaluating obefazimod in UC with a placebo-adjusted clinical remission rate of 16.4% at the 50 mg dose, exceeding market expectations of 12-13% - clearly representing a bull case for the stock. The favourable safety/tolerabi
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.